Botanix Pharmaceuticals Limited (BXPHF) Research

Botanix Pharmaceuticals Limited, an Australian company established in Leederville in 1984, specializes in the research and development of novel dermatological and antimicrobial solutions. The company's core mission involves creating innovative treatments for a range of common skin conditions and infections. Its promising product pipeline includes: Sofpironium Bromide: An investigational medication for primary axillary hyperhidrosis, which has successfully completed Phase 3 clinical trials. BTX 1503: A transdermal gel formulation designed to treat severe acne in both adult and teenage patients, having concluded Phase II clinical studies. BTX 1801: This candidate has finished Phase IIb clinical trials for addressing Staphylococcus aureus and Methicillin-resistant Staphylococcus aureus (MRSA) infections. BTX 1702: Currently undergoing Phase IIb clinical trials for the treatment of papulopustular rosacea. BTX 1204A: Aimed at treating atopic dermatitis.

Market snapshot

Symbol
BXPHF
Price
$0.02
Day change
0.00%
Market cap
$43.8M
P/E ratio
-0.49x
52-week range
0.013-0.29
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$0.27

Peer companies

  • Ascend Wellness Holdings, Inc. (AAWH)
  • Brii Biosciences Limited (BRIBF)
  • Hofseth BioCare ASA (HOFBF)
  • Innate Pharma S.A. (IPHYF)
  • JW (Cayman) Therapeutics Co. Ltd (JWCTF)
  • Kintor Pharmaceutical Limited (KNTPF)
  • Molecular Partners AG (MLLCF)
  • NDT Pharmaceuticals Inc. (NDTP)

Open Botanix Pharmaceuticals Limited (BXPHF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.